Know the Signs of Rare But Deadly Gall Bladder, Bile Duct Cancers
Title: Know the Signs of Rare But Deadly Gall Bladder, Bile Duct CancersCategory: Health NewsCreated: 2/16/2021 12:00:00 AMLast Editorial Review: 2/16/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 16, 2021 Category: Cancer & Oncology Source Type: news

Combining PD-1inhibitor with VEGF inhibitor in chemotherapy of cholangiocarcinoma patient
(Bentham Science Publishers) Cholangiocarcinoma is the second most frequent liver cancer. Many patients miss the opportunity of having a surgery performed on them and its control has always been considered difficult. Here, doctors from The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China, present a case of stage 4 cholangiocarcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2021 Category: Cancer & Oncology Source Type: news

Discovery of a new approach to inhibiting a highly treatment-refractory liver cancer
(Massachusetts General Hospital) Blocking placental growth factor (PlGF), a member of the vascular endothelial growth factor family, inhibits the progression of intrahepatic cholangiocarcinoma (ICC) and enhances the efficacy of chemotherapy in mouse models. This novel approach to targeting the connective tissue microenvironment of ICC, a rare but notoriously treatment-resistant form of liver cancer, could pave the way for combination therapies, including chemotherapy and immune checkpoint blockade. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 12, 2021 Category: Cancer & Oncology Source Type: news

What Is the Survival Rate of Cholangiocarcinoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - December 30, 2020 Category: General Medicine Source Type: news

Proton Pump Inhibitors and Odds of Cholangiocarcinoma Proton Pump Inhibitors and Odds of Cholangiocarcinoma
Proton pump inhibitors have been reported to be associated with cholangitis. Might they increase the risk of cholangiocarcinoma?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 2, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

BridgeBio Pharma And Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma
PALO ALTO, CA– December 1, 2020– BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 1, 2020 Category: Drugs & Pharmacology Source Type: news

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
(University of Texas M. D. Anderson Cancer Center) In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 17, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Scientists discover a new mechanism controlling liver cancer development
This study, published in PNAS, shows that the PPARα protein, when blocked, dramatically reduces the impact and progression of cholangiocarcinoma (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 1, 2020 Category: Cancer & Oncology Source Type: news

Ivosidenib Promising Against Refractory Bile Duct Cancer Ivosidenib Promising Against Refractory Bile Duct Cancer
Ivosidenib improved progression-free survival in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma in a phase 3 placebo-controlled trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pemazyre Approved for Treatment of Advanced Cholangiocarcinoma
Title: Pemazyre Approved for Treatment of Advanced CholangiocarcinomaCategory: Health NewsCreated: 4/21/2020 12:00:00 AMLast Editorial Review: 4/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 21, 2020 Category: Cancer & Oncology Source Type: news

Pemazyre Approved for Treatment of Advanced Cholangiocarcinoma
MONDAY, April 20, 2020 -- Pemazyre (pemigatinib) has been granted accelerated approval for the treatment of advanced cholangiocarcinoma, the U.S. Food and Drug Administration announced Friday. The drug approval is indicated for previously treated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2020 Category: General Medicine Source Type: news

FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion
Oncology News burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 20, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news